Aligos Therapeutics (ALGS) Return on Equity (2020 - 2026)

Aligos Therapeutics has reported Return on Equity for 7 years, with the latest figure at 0.02% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity fell 1.0% year-over-year to 0.02%; the trailing twelve-month figure through Mar 2026 stood at 0.02% (down 1.0% YoY), and the FY2025 full-year result was 0.02%, up 2.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.02%, down from 0.0% in the prior quarter.
• The five-year high for Return on Equity was 0.0% in Q4 2025, with the low at 0.12% in Q4 2024.
• Historically, Return on Equity has averaged 0.02% across 5 years, with a median of 0.01% in 2023.
• Annual changes were most pronounced in 2024 — Return on Equity fell 11 bps — and 2025, when it grew 12 bps.
• Aligos Therapeutics' Return on Equity stood at 0.01% in 2022, then plunged by 40 bps to 0.01% in 2023, then slumped by 941 bps to 0.12% in 2024, then jumped by 97 bps to 0.0% in 2025, then sank by 449 bps to 0.02% in 2026.
• The last three Return on Equity figures came in at 0.02% (Q1 2026), 0.0% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.